Novartis Ag

Bristol-Myers Squibb Compnay

Scott, Jeffrey

Lau, Yvonne

David E Lebwohl

Malte Peters

Heidi Lane

William Raj Sellers

Peter Wayne Marks

Nanxin Li

Maurizio Voi

Yvonne Lau

John Benedetto

Ingrid Elmroth

Michael Stumm

William Berg

Jeffrey Scott

Disclosed is a combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of: 1) a c-MET inhibitor; 2) a CDK4/6 inhibitor; 3) a PI3K inhibitor; 4) a BRAF inhibitor; 5) an FGFR inhibitor; 6) a MEK inhibitor, or 7) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.

Combination therapies

Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.

Combination therapies of EGFR inhibitors

A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.

Neuroendocrine tumor treatment

Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative diseases.

Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Prevention or treatment of pain by administration of an endothelin antagonist.

Method for preventing or treating pain by administering an endothelin antagonist

Growing community of inventors

Madison, CT, United States of America

David E Lebwohl